Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil

Vista sencilla de ítem
dc.creatorSilveira, Mariângela F
dc.creatorBarros, Aluísio J D
dc.creatorHorta, Bernardo L
dc.creatorPellanda, Lúcia C
dc.creatorVictora, Gabriel D
dc.creatorDellagostin, Odir A
dc.creatorStruchiner, Claudio J
dc.creatorBurattini, Marcelo N
dc.creatorValim, Andréia R M
dc.creatorBerlezi, Evelise M
dc.creatorMesa, Jeovany M
dc.creatorIkeda, Maria Letícia R
dc.creatorMesenburg, Marilia A
dc.creatorMantesso, Marina
dc.creatorDall'Agnol, Marinel M
dc.creatorBittencourt, Raqueli A
dc.creatorHartwig, Fernando P
dc.creatorMenezes, Ana M B
dc.creatorBarros, Fernando C
dc.creatorHallal, Pedro C
dc.creatorVictora, Cesar G
dc.date.accessioned2020-07-17T14:59:06Z
dc.date.available2020-07-17T14:59:06Z
dc.date.created2020-07-08
dc.description.abstractenglishPopulation-based data on COVID-19 are urgently needed. We report on three rounds of probability sample household surveys in the state of Rio Grande do Sul (Brazil), carried out in nine large municipalities using the Wondfo lateral flow point-of-care test for immunoglobulin M and G antibodies against SARS-CoV-2 (https://en.wondfo.com.cn/product/wondfo-sars-cov-2-antibody-test-lateral-flow-method-2/). Before survey use, the assay underwent four validation studies with pooled estimates of sensitivity (84.8%; 95% confidence interval (CI) = 81.4–87.8%) and specificity (99.0%; 95% CI = 97.8–99.7%). We calculated that the seroprevalence was 0.048% (2/4,151; 95% CI = 0.006–0.174) on 11–13 April (round 1), 0.135% (6/4,460; 95% CI = 0.049–0.293%) on 25–27 April (round 2) and 0.222% (10/4,500; 95% CI = 0.107–0.408) on 9–11 May (round 3), with a significant upward trend over the course of the surveys. Of 37 family members of positive individuals, 17 (35%) were also positive. The epidemic is at an early stage in the state, and there is high compliance with social distancing, unlike in other parts of Brazil. Periodic survey rounds will continue to monitor trends until at least the end of September, and our population-based data will inform decisions on preventive policies and health system preparedness at the state level.spa
dc.format.extent8 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1038/s41591-020-0992-3spa
dc.identifier.issn1546-170Xspa
dc.identifier.otherhttps://www.nature.com/articles/s41591-020-0992-3spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/10731
dc.publisherScience Directeng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectAnticuerposspa
dc.subject.keywordPopulation-based surveysspa
dc.subject.keywordAntibodiesspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titlePopulation-based surveys of antibodies against SARS-CoV-2 in Southern Brazilspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
s41591-020-0992-3.pdf
Tamaño:
1.58 MB
Formato:
Adobe Portable Document Format
Descripción:
Documento reservado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS